Congress empowers the FDA to act on cyber threats in medical devices

by

Chris Harvey, senior vice president, Sedgwick brand protection, explains the findings of its report in medical device recalls. 

PeopleImages.com - Yuri A Shutterstock

As medical devices become increasingly connected to the Internet and other digital networks, they also become more vulnerable to cyber-attacks. This poses a threat to the safety and privacy of patients. This heightened risk has become a major concern for the healthcare industry. Several high-profile incidents were reported in recent years affecting a range of devices including IV pumps, MRI machines and heart rate monitors.

Reasons for the rise in cybersecurity threats to medical devices

 There are several factors leading to the increased risk of cyber-attacks for medical devices:

To help reduce this growing threat, the Consolidated Appropriations Act, 2023 (H.R. 2617) that was signed in December 2022 included provisions aimed at improving the cybersecurity of medical devices. The omnibus appropriations bill also gave the FDA the authority to establish and enforce cybersecurity standards for medical devices for the first time.

How the Consolidated Appropriations Act will help

In addition to giving the FDA more regulatory authority, the Consolidated Appropriations Act (the Act) includes several provisions to improve the cybersecurity of medical devices:

The impact on medical device recalls

Medical device recalls are also impacted by the new Consolidated Appropriations Act. The Act requires medical device manufacturers to include cybersecurity information in their recall reports to the FDA. This information will help the FDA and healthcare providers better understand the cybersecurity risks associated with recalled medical devices.

In addition, the FDA must provide guidance to medical device manufacturers on how to conduct cybersecurity-focused post-market reviews of medical devices. This guidance will help manufacturers identify and address cybersecurity vulnerabilities in devices that are already on the market. By addressing these vulnerabilities, manufacturers can reduce the risk of future recalls due to cybersecurity issues.

The FDA is also required to establish a pilot program to assess the effectiveness of medical device cybersecurity vulnerability reporting. This program will provide the FDA with valuable data on cybersecurity risks and help the agency identify areas where additional measures may be needed.

Overall, the provisions included in the new Act will have a significant impact on medical device security and product recalls, as well as on patient safety. By requiring manufacturers to include cybersecurity information in recall reports, providing guidance on post-market reviews, and establishing a pilot program to assess the effectiveness of vulnerability reporting, the legislation will help reduce the risk of recalls due to cybersecurity issues.

This will not only benefit patients but will also help to reduce the financial and reputational risk to manufacturers that often results from product recalls.

Back to topbutton